510 results on '"Marron, Thomas"'
Search Results
2. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
3. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
4. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
5. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
6. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
7. Optimizing care in early phase cancer trials: The role of palliative care
8. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
9. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
10. Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
11. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
12. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
13. Immunotherapy and Liver Transplantation: The Future or the Failure?
14. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
15. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
16. Circulating proteins to predict COVID-19 severity
17. SIGLEC9 tips the myeloid balance in glioblastoma
18. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae
19. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
20. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
21. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
22. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC
23. Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals
24. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals
25. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
26. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
27. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
28. Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody
29. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells
30. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
31. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
32. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients
33. Single cell view of tumor microenvironment gradients in pleural mesothelioma
34. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
35. Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.
36. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study
37. An inflammatory cytokine signature predicts COVID-19 severity and survival
38. A conserved dendritic-cell regulatory program limits antitumour immunity
39. Local Immunotherapies of Cancer
40. Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children
41. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
42. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
43. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
44. 1043 Intratumoral mRNA IL-12 can induce a dose dependent immunostimulatory effect within tumor microenvironment in patients with advanced solid tumors
45. 650 Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
46. Benefits and Challenges of Lung Cancer Screening in Older Adults
47. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
48. PB2258: PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID TUMOURS AND LYMPHOMAS.
49. Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
50. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.